Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > This game isn’t over $$$

<< Previous

Bullboard Posts

Next >>

Comment by Mole101on Apr 01, 2021 10:51pm

88 Views

Post# 32926060

RE:RE:RE:RE:RE:RE:This game isn’t over $$$

Bear is in love with Arch Biopartnets , (The company is developing a drug platform Metablok to produce drug candidates to inhibit organ inflammation caused via the DPEP-1 pathway.)... I think he views this as a" I win you loose" kind of game and that's why he comes by ones in a wile , just to make himself feel good about his investment .

Qtrlbder wrote: Sound like a paid basher

Laliberte2020 wrote:
Speaking of Stockholm syndrome, you hate the stock and the company but you come here everyday.............. And the way I read it is the high dose is not more effective than the low dose, not ineffective. Glta